C Katlama1, C Soulié2, F Caby3, A Denis4, C Blanc3, L Schneider3, M-A Valantin3, R Tubiana3, M Kirstetter4, E Valdenassi4, Thuy Nguyen2, G Peytavin5, V Calvez2, A-G Marcelin2. 1. Hôpital Pitié-Salpêtrière, Infectious Diseases Department, 75013 Paris, France Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), 75013 Paris, France christine.katlama@aphp.fr. 2. Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), 75013 Paris, France Hôpital Pitié-Salpêtrière, Department of Virology, Paris, France. 3. Hôpital Pitié-Salpêtrière, Infectious Diseases Department, 75013 Paris, France Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), 75013 Paris, France. 4. Hôpital Pitié-Salpêtrière, Infectious Diseases Department, 75013 Paris, France. 5. Pharmaco-Toxicology Department, APHP, Bichat-Claude Bernard Hospital, Université Paris Diderot, Sorbonne Paris Cité, IAME, INSERM UMR 1137, Paris, France.
Abstract
BACKGROUND: Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high potency, long half-life and high genetic barrier, offers potential for monotherapy. METHODS: This observational single-centre study enrolled all patients with HIV RNA (viral load) <50 copies/mL for at least 12 months, with CD4 >350 cells/mm(3) and with no failure under integrase inhibitor therapy who had switched from suppressive ART to dolutegravir monotherapy (50 mg/day). Primary outcome was proportion of patients with viral load <50 copies/mL at week 24. RESULTS: Twenty-eight patients treated for a median ART duration of 17 years (IQR 11-20), virally suppressed for a median of 79 months (IQR 42-95) and with a median CD4 count of 624 cells/mm(3) (IQR 524-761), were enrolled. Baseline ART consisted of a three-drug (n = 10), two-drug (n = 10) or single-drug (n = 8) regimen with integrase inhibitor exposure in 13 patients. The proportion of patients maintaining viral load <50 copies/mL was 96% (95% CI 79%-100%) at week 4, 100% (95% CI = 85%-100%) at week 8, 93% (95% CI 76%-99%) at week 12 and 92% (75-99) at week 24. Three patients (3.70%; 95% CI 3.4%-10.8%) with prior integrase inhibitor experience had HIV RNA rebound with the presence of resistance mutations. Genotyping of HIV DNA using the Sanger method or ultradeep sequencing showed no integrase inhibitor resistance-associated mutations (RAMs) except for the mutation 74I in a patient on a suppressive elvitegravir regimen. The median within- and between-subject variability of dolutegravir C24 was 25% and 34%, respectively. Nine patients with a year of follow-up remained virally suppressed. CONCLUSIONS: Dolutegravir has the potency to be further investigated as a single ART in randomized studies, particularly in patients with no prior exposure to integrase inhibitors.
BACKGROUND: Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high potency, long half-life and high genetic barrier, offers potential for monotherapy. METHODS: This observational single-centre study enrolled all patients with HIV RNA (viral load) <50 copies/mL for at least 12 months, with CD4 >350 cells/mm(3) and with no failure under integrase inhibitor therapy who had switched from suppressive ART to dolutegravir monotherapy (50 mg/day). Primary outcome was proportion of patients with viral load <50 copies/mL at week 24. RESULTS: Twenty-eight patients treated for a median ART duration of 17 years (IQR 11-20), virally suppressed for a median of 79 months (IQR 42-95) and with a median CD4 count of 624 cells/mm(3) (IQR 524-761), were enrolled. Baseline ART consisted of a three-drug (n = 10), two-drug (n = 10) or single-drug (n = 8) regimen with integrase inhibitor exposure in 13 patients. The proportion of patients maintaining viral load <50 copies/mL was 96% (95% CI 79%-100%) at week 4, 100% (95% CI = 85%-100%) at week 8, 93% (95% CI 76%-99%) at week 12 and 92% (75-99) at week 24. Three patients (3.70%; 95% CI 3.4%-10.8%) with prior integrase inhibitor experience had HIV RNA rebound with the presence of resistance mutations. Genotyping of HIV DNA using the Sanger method or ultradeep sequencing showed no integrase inhibitor resistance-associated mutations (RAMs) except for the mutation 74I in a patient on a suppressive elvitegravir regimen. The median within- and between-subject variability of dolutegravir C24 was 25% and 34%, respectively. Nine patients with a year of follow-up remained virally suppressed. CONCLUSIONS:Dolutegravir has the potency to be further investigated as a single ART in randomized studies, particularly in patients with no prior exposure to integrase inhibitors.
Authors: Alonso Heredia; Said Hassounah; Sandra Medina-Moreno; Juan C Zapata; Nhut M Le; Yingshan Han; James S Foulke; Charles Davis; Joseph Bryant; Robert R Redfield; Mark A Wainberg Journal: J Antimicrob Chemother Date: 2017-09-01 Impact factor: 5.790
Authors: Hanh T Pham; Lydia Labrie; Ingeborg E A Wijting; Said Hassounah; Ka Yee Lok; Inna Portna; Mark E Goring; Yingshan Han; Cynthia Lungu; Marchina E van der Ende; Bluma G Brenner; Charles A Boucher; Bart J A Rijnders; Jeroen J A van Kampen; Thibault Mesplède; Mark A Wainberg Journal: J Infect Dis Date: 2018-07-24 Impact factor: 5.226
Authors: Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg Journal: J Virol Date: 2019-01-04 Impact factor: 5.103
Authors: Alina Kirichenko; Ilya Lapovok; Pavel Baryshev; David A M C van de Vijver; Jeroen J A van Kampen; Charles A B Boucher; Dimitrios Paraskevis; Dmitry Kireev Journal: Viruses Date: 2020-07-31 Impact factor: 5.048